Predicting treatment-outcome in cocaine dependence from admission urine drug screen and peripheral serotonergic measures.
We investigated whether urine drug screens (UDS) at admission and platelet paroxetine binding, a measure of serotonin transporter sites, were related to outcome measures for cocaine patients in treatment. Tritiated paroxetine binding sites on platelets were assayed and UDS were obtained for 105 African American cocaine-dependent outpatients. Outcome measures included number of negative urines, days in treatment, dropouts, and number of treatment sessions attended. A significant association was found between cocaine-positive UDS at admission and negative urines, treatment retention, dropouts, and treatment sessions; while Bmax values of paroxetine binding (density of serotonin transporter sites) were significantly associated with treatment retention and negative urines. Moreover, UDS and paroxetine binding combined to enhance prediction of retention and abstinence. Although both admission UDS and paroxetine binding seem to contribute individually in predicting outcome of cocaine patients, a combination of the two variables seems to have a stronger effect in terms of predicting treatment-outcome.
Division of Substance Abuse Programs, Department of Psychiatry and Human Behavior, Thomas Jefferson University, 833 Chestnut Street East, Suite 210E, Philadelphia, PA 19107, USA. ashwin.patkar@mail.tju.edu
Ashwin A
AA
Patkar
Charles C
CC
Thornton
Wade H
WH
Berrettini
Edward
E
Gottheil
Stephen P
SP
Weinstein
Kevin P
KP
Hill
D000328:Adult; D044383:Black People; D001792:Blood Platelets / Q000378:metabolism; D002352:Carrier Proteins / Q000378:metabolism*; D019970:Cocaine-Related Disorders / Q000097:blood* / Q000175:diagnosis / Q000534:rehabilitation / Q000652:urine*; D005260:Female; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000378:metabolism*; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; D010045:Outpatients / Q000706:statistics & numerical data; D017374:Paroxetine / Q000378:metabolism; D010349:Patient Compliance; D010352:Patient Dropouts; D011379:Prognosis; D012701:Serotonin / Q000378:metabolism*; D050486:Serotonin Plasma Membrane Transport Proteins; D015813:Substance Abuse Detection; D016896:Treatment Outcome; D001741:Black or African American
D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D026901:Membrane Transport Proteins; D009419:Nerve Tissue Proteins; C493230:SLC6A4 protein, human; D050486:Serotonin Plasma Membrane Transport Proteins; D012701:Serotonin; D017374:Paroxetine